CLGN - CollPlant Biotechnologies Ltd.
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 7.11 |
| Open | 7.14 |
| Bid | 6.33 x 900 |
| Ask | 11.08 x 800 |
| Day's Range | 6.94 - 7.25 |
| 52 Week Range | 4.27 - 13.97 |
| Volume | |
| Avg. Volume | 7,932 |
| Market Cap | 82.541M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.46 |
| Earnings Date | Aug 23, 2023 - Aug 28, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.92 |
Fair Value
Related Research
PR NewswireCollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update on its programs.
PR NewswireCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the first quarter of 2023 on May 24, 2023, before the market open. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on May 24th at 10:00 am Eastern Dayl
Business WireStratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs
EDEN PRAIRIE, Minn. & REHOVOT, Israel, April 04, 2023--Stratasys Ltd. (Nasdaq: SSYS) and CollPlant Biotechnologies (Nasdaq: CLGN) today announced a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks. The first project focuses on the development of an industrial-scale solution for CollPlant's regenerative breast implants
PR NewswireCollplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2022 and provided a corporate update on its programs.
PR NewswireCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the full year ended December 31, 2022, on March 29, 2023, before the market open. The Company will then host a conference call and webcast to discuss its financial results along with corporate updates on March 29th
PR NewswireCollPlant Issues Letter to Shareholders
CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal, to its shareholders.
PR NewswireCollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives
CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced that it has successfully completed a large animal study for its recombinant human collagen (rhCollagen)-based 3D bioprinted regenerative breast implants, addressing the $2.5 billion global breast implant market. Supported by these promising results, the Company is planning to initiate a follow-up large animal study dur
PR NewswireCollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form
CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the launch of Collink.3DTM 50L, a recombinant human collagen (rhCollagen)-based bioink in a powder form for use in a wide range of 3D bioprinting applications, including drug discovery, drug screening, tissue testing as well as the development of transplantable tissues and organs.
Simply Wall St.We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
PR NewswireCollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended September 30, 2022 and provided an update on the Company's business developments.
PR NewswireCollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis
CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products, together with Ramot, the Technology Transfer Company of Tel Aviv University and Sheba Medical Center, a hospital ranked by Newsweek magazine as one of the Top 10 world best hospitals for the 4th consecutive year (2019-2022), today announced entering into a license and research agreement to co-develop a 'Gut-on-a-Chip' tissue model for drug discovery and hi
PR NewswireCollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D™ 90
CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the Company is launching Collink.3D™ 90, a recombinant human collagen (rhCollagen)-based bioink for use in a variety of 3D bioprinting applications. Collink.3D™ 90 is complementary to the Company's first commercial bioink, Collink.3D™ 50, which was launched late last year, offering increased
PR NewswireCollPlant to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17
CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative human-collagen based technologies and products for tissue regeneration and organ manufacturing, today announced that Eran Rotem, Collplant's Deputy CEO and Chief Financial Officer, will present a company overview at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum at the Westin NY Grand Central Hotel.
PR NewswireCollPlant to present at the Dawson James Small Cap Growth Conference on October 12
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that the Company's Deputy CEO & Chief Financial Officer Eran Rotem, will present a company overview at the Dawson James 7th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida.
PR NewswireCollPlant to Present at the International Conference on Biofabrication 2022 in Tuscany, Italy
CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the Company will make a presentation on "Recombinant Human Collagen-based Bioinks for Biofabrication and Modeling Applications" at the International Conference on Biofabrication on September 28th. CollPlant will also have an exhibition booth at the Conference from Sept 25th-28th.
PR NewswireCollPlant Biotechnologies to Participate in September Investor Conferences
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced that Deputy CEO and CFO Eran Rotem will participate in investor conferences later this month.
PR NewswireCollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results
CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the second quarter ended June 30, 2022 and provided an update on the Company's business developments.
- Simply Wall St.
We're Hopeful That CollPlant Biotechnologies (NASDAQ:CLGN) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
PR NewswireCollPlant to Present and Exhibit at TERMIS Annual Conference in Toronto, Canada
CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that the company will deliver two presentations, and will have an exhibition booth at the annual conference and exhibition of the Tissue Engineering and Regenerative Medicine International Society (TERMIS), in Toronto, Canada, on July 10-13, 2022.
PR NewswireCollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study
CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the initiation of a study in large animals for its 3D bioprinted regenerative breast implant program, addressing the $2.8 billion global breast implant market.